Markets:

Overview

News

Currencies

International

Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

58.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 23, 2024

Via Benzinga

Why RAPT Therapeutics Stock Gained Over 100% On Monday? ↗

December 23, 2024

RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies. $35M upfront payment.

Via Benzinga

US Stocks Mixed, Dow Tumbles 150 Points ↗

December 23, 2024

Via Benzinga

Topics Stocks

RAPT Therapeutics Announces $150 Million Private Placement

December 23, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics: Q4 Earnings Insights ↗

March 07, 2024

Via Benzinga

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

December 23, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

November 12, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 11, 2024

Via Benzinga

Crude Oil Down 3%; Aramark Posts Upbeat Earnings ↗

November 11, 2024

Via Benzinga

Nasdaq Moves Lower; Canaan Shares Surge ↗

November 11, 2024

Via Benzinga

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury ↗

November 11, 2024

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

Via Benzinga

Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results ↗

November 11, 2024

Via Benzinga

Topics Stocks

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

November 11, 2024

Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities

From RAPT Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 06, 2024

Via Benzinga

10 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 02, 2024

Via Benzinga

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024 ↗

August 08, 2024

RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

August 08, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 03, 2024

Via Benzinga

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗

May 21, 2024

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

May 09, 2024

From Schall Law

Via GlobeNewswire

What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday? ↗

May 09, 2024

RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.

Via Benzinga

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 09, 2024

Via Benzinga

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024 ↗

May 09, 2024

RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 09, 2024

Via Benzinga

RAPT Therapeutics Reports First Quarter 2024 Financial Results

May 09, 2024

Company maintains solid cash position of $141.6 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

April 09, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

3 Biotech Stocks to Dump Before They Go to Zero ↗

April 09, 2024

These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.

Via InvestorPlace

RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm

March 11, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023 ↗

March 07, 2024

RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.